Our commitment to ensuring quality healthcare began back in 1972.

As Riga’s pharmaceutical factories were unable to produce the required amount of medication, in 1968 the construction of Olaine Chemical-Pharmaceutical Plant was started. It was one of the most important five-year construction projects, along with the construction of Riga HPP and Inčukalns gas storage. The construction of the plant lasted three years, and during its process the surrounding environment changed significantly: the place where the factory was built was marshy, with small sand dunes.

The first synthesis of furagin was carried out on October 10th. That day is considered to be the start of the company’s operations, which at that time was called Olaines ķīmiski-farmaceitiskā rūpnīca (Olaine Chemical-Pharmaceutical Plant).

The company has always paid special attention to ecological research, ensuring the surrounding environment against chemical and wastewater pollution. In March 1989, a special laboratory for the ecology of the production area was established, where research on toxicological evaluation of wastewater was carried out. The air quality in the industrial area was also studied and analysed.

The beginning of the nineties was marked by radical changes in the whole Latvian economy, including industrial production. One of the words that characterised this time was “deficit”. There was a lack of raw materials and products. Various medicines were not available in pharmacies.

The 2000s were an era of successful ambition. Focus on quality enabled the company to obtain multiple quality certificates and start exporting to even more new markets. The high business potential was also reflected in the stock market.

As the company kept on expanding internationally, new subsidiaries were added to the group. New milestones were achieved. Success was reflected both by financial performance as well as recognition in the form of many business awards.

With the ever-changing global politics, the company is working hard to enter new export markets, covering Western Europe, the Middle East, North Africa and North America. For that, a new brand identity, suitable for the new markets is introduced. In parallel, 100+ new products are being developed to make healthcare reachable all over the world.